BSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,335.40
- Market cap
- ₹1,11,463 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 39.8×Sector 46.5×
- Promoter holding
- 26.63%-0.01% QoQ
- FII holding
- 20.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
- Call
- Guides 25% growth
Dr. Reddy's Laboratories Investor Presentation: Key Takeaways
Q2FY27 revenue ₹8,671 Cr (-1.5% YoY), EBITDA ₹1,783 Cr (20.6%), PAT ₹925 Cr (-36% YoY). Management stresses double-digit base-business growth excluding lenalidomide in North America.
Dr. Reddy's Laboratories Q2 FY27 Results: Net Profit ₹913.2 Cr, Down 31.7% YoY
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,698 Cr (-1.5% YoY) and net profit of ₹913.2 Cr (-31.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹913.2 Cr · -31.7% YoY
Dr. Reddy's Laboratories Other Announcement
Dr. Reddy's Laboratories Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, including notes on significant beneficial ownership.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's received DCGI approval for Zytorvi in advanced esophageal cancer, its second Indian indication. This expands first-line immunotherapy access in its oncology portfolio.
Other management change announcements
All →Sayaji Hotels (Indore) Management Change
Sayaji Hotels (Indore) appointed Azhar Yusuf Dhanani as Additional Non-Executive Non-Independent Director effective October 28, 2026. Shareholder approval is required within three months.
Fabtech Technologies Management Change
FABTECH Technologies appointed Mr. Alan Dias as Vice President - HR, a senior management personnel role, effective October 28, 2026. He brings over 24 years of human resources experience.
Parmax Pharma Management Change
Parmax Pharma's independent director Ami Shah resigned effective October 28, 2026. The exit follows a change in management and control of the company.
Sagarsoft (India) Management Change
Sagarsoft (India) appointed Ms. Arcot Ganeshan Monisha as Company Secretary and Compliance Officer, designated as KMP, effective 28 October 2026. Details are provided per Regulation 30 in the annexure.
Chemfab Alkalis Management Change
Chemfab Alkalis approved unaudited Q2/H1 results, committee re-designations, and appointed V. R. Raguraman as Chief Operating Officer (SMP). The senior management appointment is the filing's main business event.
Aeroflex Industries Management Change
Aeroflex Industries reports Drashti Bhil's change from Deputy CFO to CFO, plus Mustafa Kachwala's tenure completion as CFO effective 27 November 2026. Management reshuffle with no money or business event.